title: Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA.
abstract: Recently, serum Golgi protein 73 (GP73) levels have been found to be elevated in patients with hepatocellular carcinoma (HCC), and GP73 has been proposed as a novel marker for HCC. However, GP73 levels in patients remain controversial due to the specificity of the anti-GP73 antibody-based enzyme linked immunosorbent assay (ELISA). Therefore, an anti-GP73 antibody with high specificity was highly demanded. In the present study, by hybridoma screening, we generated an anti-GP73 monoclonal antibody (mAb) designated as 6A2 using recombinant GP73 protein produced by prokaryotic expression. The specificity of 6A2 was evaluated by Western blotting, immunohistochemistry and immunoprecipitation. The results showed that 6A2 recognized GP73 in both native and denatured forms. In addition, we have developed a sandwich ELISA using 6A2 and GP73 polyclonal antibody generated in New Zealand white rabbits according to standard procedures, and measured the serum GP73 level of patients using this assay. Our results showed that serum GP73 levels of HCC patients were significantly higher than those of healthy controls (P = 0.0036). Furthermore, for the first time, GP73 serum level was found to be elevated in patients with breast cancer compared with healthy controls (P = 0.0172).
authors.affiliation: Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 210029, China;
authors.forename: Aixia
authors.initials: A
authors.lastname: Zhang
authors.forename: Brian
authors.initials: B
authors.lastname: Cao
keywords: GP73; Western blotting; hepatocellular carcinoma; monoclonal antibody; sandwich ELISA
references.citation: Mol Cell Proteomics. 2002 Nov;1(11):845-67
references.pmid: 12488461
references.citation: BMC Cancer. 2012 Jan 16;12:17
references.pmid: 22244200
references.citation: Ann Clin Biochem. 2009 Jan;46(Pt 1):38-43
references.pmid: 19008260
references.citation: Med Oncol. 2010 Jun;27(2):339-45
references.pmid: 19399652
references.citation: Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):779-84
references.pmid: 15642945
references.citation: Hepatology. 2009 May;49(5):1602-9
references.pmid: 19291786
references.citation: Br J Cancer. 2008 Sep 16;99(6):939-48
references.pmid: 18781151
references.citation: Traffic. 2002 Sep;3(9):641-53
references.pmid: 12191016
references.citation: J Hepatol. 2005 Dec;43(6):1007-12
references.pmid: 16137783
references.citation: Traffic. 2007 Oct;8(10):1415-23
references.pmid: 17662025
references.citation: Gut. 2010 Dec;59(12):1687-93
references.pmid: 20876776
references.citation: Curr Protoc Protein Sci. 2004 Feb;Chapter 13:Unit 13.6
references.pmid: 18429250
references.citation: Am J Gastroenterol. 2004 Jun;99(6):1087-95
references.pmid: 15180730
references.citation: Neoplasia. 2008 Nov;10(11):1285-94
references.pmid: 18953438
references.citation: Hepatology. 2009 May;49(5):1421-3
references.pmid: 19402061
references.citation: Hepatology. 2002 Jun;35(6):1431-40
references.pmid: 12029628
references.citation: Prostate. 2008 Sep 15;68(13):1387-95
references.pmid: 18543251
references.citation: Gene. 2000 May 16;249(1-2):53-65
references.pmid: 10831838
references.citation: Hybrid Hybridomics. 2003 Feb;22(1):33-9
references.pmid: 12713688